Interim analysis of the use of the anti-idiotype breast cancer vaccine 11D10 (TriAb®) in conjunction with autologous stem cell transplantation in patients with metastatic breast cancer

Donna E. Reece; Kenneth A. Foon; Malaya Battacharya-Chatterjee; Doug Adkins; E. Randolph Broun; D. Gerald Connaghan; John F. Dipersio; H. Kent Holland; Dianna S. Howard; Greg A. Hale; Hans G. Klingemann; Rita K. Munn; Anastasios Raptis; Gordon L. Phillips

doi:10.3816/CBC.2001.n.011

Interim analysis of the use of the anti-idiotype breast cancer vaccine 11D10 (TriAb®) in conjunction with autologous stem cell transplantation in patients with metastatic breast cancer

Donna E. Reece
, Kenneth A. Foon
, Malaya Battacharya-Chatterjee
, Doug Adkins
, E. Randolph Broun
, D. Gerald Connaghan
, John F. Dipersio
, H. Kent Holland
, Dianna S. Howard
, Greg A. Hale
, Hans G. Klingemann
, Rita K. Munn
, Anastasios Raptis
, Gordon L. Phillips

Research output: Contribution to journal › Article › peer-review

9 Scopus citations

Abstract

The anti-idiotype monoclonal antibody breast cancer vaccine 11D10 (TriAb®) was administered before and after autologous stem cell transplantation (ASCT) in 45 patients with metastatic breast cancer whose disease was responsive to conventional chemotherapy. Evidence of a positive anti-anti-idiotype antibody (Ab3) humoral response was noted at a median of 1.75 months post-ASCT (range, before ASCT-6 months) with this strategy. Maximal Ab3 levels and idiotype-specific T-cell proliferative responses were observed at a median of 3 and 4 months, respectively, after ASCT. The achievement of rapid immune responses after ASCT, during a known period of decreased immunoresponsiveness, opens the possibility of an additional antitumor effect at a time when the tumor burden is relatively small. Moreover, in this interim analysis, patients with the most vigorous humoral and cellular immune responses had a significant improvement in progression-free survival. Further follow-up and evaluation of this approach is warranted.

Original language	English
Pages (from-to)	52-58
Number of pages	7
Journal	Clinical breast cancer
Volume	2
Issue number	1
DOIs	https://doi.org/10.3816/CBC.2001.n.011
State	Published - Apr 2001

Keywords

Autotransplantation
Human milk fat globule
T-cell proliferative response
TriAb breast cancer vaccine

Access to Document

10.3816/CBC.2001.n.011

Cite this

Reece, D. E., Foon, K. A., Battacharya-Chatterjee, M., Adkins, D., Broun, E. R., Connaghan, D. G., Dipersio, J. F., Holland, H. K., Howard, D. S., Hale, G. A., Klingemann, H. G., Munn, R. K., Raptis, A., & Phillips, G. L. (2001). Interim analysis of the use of the anti-idiotype breast cancer vaccine 11D10 (TriAb®) in conjunction with autologous stem cell transplantation in patients with metastatic breast cancer. Clinical breast cancer, 2(1), 52-58. https://doi.org/10.3816/CBC.2001.n.011

@article{32f75c708a774d2c80148cf00444737c,

title = "Interim analysis of the use of the anti-idiotype breast cancer vaccine 11D10 (TriAb{\textregistered}) in conjunction with autologous stem cell transplantation in patients with metastatic breast cancer",

abstract = "The anti-idiotype monoclonal antibody breast cancer vaccine 11D10 (TriAb{\textregistered}) was administered before and after autologous stem cell transplantation (ASCT) in 45 patients with metastatic breast cancer whose disease was responsive to conventional chemotherapy. Evidence of a positive anti-anti-idiotype antibody (Ab3) humoral response was noted at a median of 1.75 months post-ASCT (range, before ASCT-6 months) with this strategy. Maximal Ab3 levels and idiotype-specific T-cell proliferative responses were observed at a median of 3 and 4 months, respectively, after ASCT. The achievement of rapid immune responses after ASCT, during a known period of decreased immunoresponsiveness, opens the possibility of an additional antitumor effect at a time when the tumor burden is relatively small. Moreover, in this interim analysis, patients with the most vigorous humoral and cellular immune responses had a significant improvement in progression-free survival. Further follow-up and evaluation of this approach is warranted.",

keywords = "Autotransplantation, Human milk fat globule, T-cell proliferative response, TriAb breast cancer vaccine",

author = "Reece, \{Donna E.\} and Foon, \{Kenneth A.\} and Malaya Battacharya-Chatterjee and Doug Adkins and Broun, \{E. Randolph\} and Connaghan, \{D. Gerald\} and Dipersio, \{John F.\} and Holland, \{H. Kent\} and Howard, \{Dianna S.\} and Hale, \{Greg A.\} and Klingemann, \{Hans G.\} and Munn, \{Rita K.\} and Anastasios Raptis and Phillips, \{Gordon L.\}",

note = "Funding Information: This study was supported by Amgen, Inc. and Titan Pharmaceuticals, Inc.",

year = "2001",

month = apr,

doi = "10.3816/CBC.2001.n.011",

language = "English",

volume = "2",

pages = "52--58",

journal = "Clinical breast cancer",

issn = "1526-8209",

number = "1",

}

Reece, DE, Foon, KA, Battacharya-Chatterjee, M, Adkins, D, Broun, ER, Connaghan, DG, Dipersio, JF, Holland, HK, Howard, DS, Hale, GA, Klingemann, HG, Munn, RK, Raptis, A & Phillips, GL 2001, 'Interim analysis of the use of the anti-idiotype breast cancer vaccine 11D10 (TriAb®) in conjunction with autologous stem cell transplantation in patients with metastatic breast cancer', Clinical breast cancer, vol. 2, no. 1, pp. 52-58. https://doi.org/10.3816/CBC.2001.n.011

Interim analysis of the use of the anti-idiotype breast cancer vaccine 11D10 (TriAb®) in conjunction with autologous stem cell transplantation in patients with metastatic breast cancer. / Reece, Donna E.; Foon, Kenneth A.; Battacharya-Chatterjee, Malaya et al.
In: Clinical breast cancer, Vol. 2, No. 1, 04.2001, p. 52-58.

Research output: Contribution to journal › Article › peer-review

TY - JOUR

T1 - Interim analysis of the use of the anti-idiotype breast cancer vaccine 11D10 (TriAb®) in conjunction with autologous stem cell transplantation in patients with metastatic breast cancer

AU - Reece, Donna E.

AU - Foon, Kenneth A.

AU - Battacharya-Chatterjee, Malaya

AU - Adkins, Doug

AU - Broun, E. Randolph

AU - Connaghan, D. Gerald

AU - Dipersio, John F.

AU - Holland, H. Kent

AU - Howard, Dianna S.

AU - Hale, Greg A.

AU - Klingemann, Hans G.

AU - Munn, Rita K.

AU - Raptis, Anastasios

AU - Phillips, Gordon L.

N1 - Funding Information: This study was supported by Amgen, Inc. and Titan Pharmaceuticals, Inc.

PY - 2001/4

Y1 - 2001/4

N2 - The anti-idiotype monoclonal antibody breast cancer vaccine 11D10 (TriAb®) was administered before and after autologous stem cell transplantation (ASCT) in 45 patients with metastatic breast cancer whose disease was responsive to conventional chemotherapy. Evidence of a positive anti-anti-idiotype antibody (Ab3) humoral response was noted at a median of 1.75 months post-ASCT (range, before ASCT-6 months) with this strategy. Maximal Ab3 levels and idiotype-specific T-cell proliferative responses were observed at a median of 3 and 4 months, respectively, after ASCT. The achievement of rapid immune responses after ASCT, during a known period of decreased immunoresponsiveness, opens the possibility of an additional antitumor effect at a time when the tumor burden is relatively small. Moreover, in this interim analysis, patients with the most vigorous humoral and cellular immune responses had a significant improvement in progression-free survival. Further follow-up and evaluation of this approach is warranted.

AB - The anti-idiotype monoclonal antibody breast cancer vaccine 11D10 (TriAb®) was administered before and after autologous stem cell transplantation (ASCT) in 45 patients with metastatic breast cancer whose disease was responsive to conventional chemotherapy. Evidence of a positive anti-anti-idiotype antibody (Ab3) humoral response was noted at a median of 1.75 months post-ASCT (range, before ASCT-6 months) with this strategy. Maximal Ab3 levels and idiotype-specific T-cell proliferative responses were observed at a median of 3 and 4 months, respectively, after ASCT. The achievement of rapid immune responses after ASCT, during a known period of decreased immunoresponsiveness, opens the possibility of an additional antitumor effect at a time when the tumor burden is relatively small. Moreover, in this interim analysis, patients with the most vigorous humoral and cellular immune responses had a significant improvement in progression-free survival. Further follow-up and evaluation of this approach is warranted.

KW - Autotransplantation

KW - Human milk fat globule

KW - T-cell proliferative response

KW - TriAb breast cancer vaccine

UR - https://www.scopus.com/pages/publications/0035022463

U2 - 10.3816/CBC.2001.n.011

DO - 10.3816/CBC.2001.n.011

M3 - Article

C2 - 11899383

AN - SCOPUS:0035022463

SN - 1526-8209

VL - 2

SP - 52

EP - 58

JO - Clinical breast cancer

JF - Clinical breast cancer

IS - 1

ER -

Interim analysis of the use of the anti-idiotype breast cancer vaccine 11D10 (TriAb®) in conjunction with autologous stem cell transplantation in patients with metastatic breast cancer

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this